SCHEMBL25823606

SCHEMBL25823606

O=C1NC(OCc2ccccc2)CCC1c1ccc(N2CCC3(CC2)CC(CO)C3)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.37
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
FFAR4 Q5NUL3 7/20 0.33
CHRM4 P08173 1/20 0.32
USP2 O75604 1/20 0.32
GAA P10253 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 2/20 0.31
SCN9A Q15858 1/20 0.31
POLB P06746 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
DDB1 Q16531 1/20 0.31
CRBN Q96SW2 1/20 0.31
IKZF3 Q9UKT9 1/20 0.31
MCHR1 Q99705 1/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25819400 0.82 GAA (0.37) ALDH1A1FFAR4GAAMAPTSMN1; SMN2
SCHEMBL25035106 0.78 CRBN (0.41) FFAR4POLBDDB1CRBN
SCHEMBL30475476 0.78 CRBN (0.41) FFAR4POLBDDB1CRBN
SCHEMBL25256285 0.68 FFAR4 (0.39) GRM5FFAR4
SCHEMBL30965622 0.68 ENPP2 (0.37) GRM5ALDH1A1CHRM4GAADDB1
SCHEMBL30981145 0.68 ENPP2 (0.39) GRM5ALDH1A1GAALMNADDB1
SCHEMBL24670689 0.67 CRBN (0.44) GAAPOLBDDB1CRBN
SCHEMBL25447026 0.66 FFAR4 (0.36) FFAR4GAAMAPTSMN1; SMN2MEN1
SCHEMBL30135932 0.66 CRBN (0.35) GRM5ALDH1A1CYP3A4LMNADDB1
SCHEMBL25819403 0.66 FFAR4 (0.42) GRM5FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 GRM5 3397/4885ALDH1A1 4008/4885KDM4E 1918/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 GRM5 1390/4885ALDH1A1 2752/4885KDM4E 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.